I'm LongbridgeAI, I can summarize articles.Metagenomi Therapeutics aims to file an IND for its hemophilia A gene-editing candidate MGX-001 by Q4 2026, targeting a first-in-human clinical trial in 2027. Preclinical data from non-human primates received top awards at the 2026 ISTH Congress. The company holds $120.7 million in cash and securities as of June 30, 2026, providing runway through Q4 2027.
- Metagenomi Therapeutics targeted a 4Q 2026 IND filing for MGX-001 in hemophilia A, setting up a potential first-in-human study in 2027. * Non-human primate preclinical findings supporting MGX-001 were already presented in scientific posters that won top awards at the 2026 ISTH Congress. * IND-enabling work is expected to finish by end-3Q 2026, positioning the program for a global clinical rollout pending regulatory clearance. * Cash, cash equivalents, and available-for-sale marketable securities totaled USD 120.7 million at June 30, 2026, with runway projected through 4Q 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metagenomi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342388), on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here